-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $52

Benzinga·01/05/2026 13:04:56
Listen to the news
Guggenheim analyst Debjit Chattopadhyay maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $64 to $52.